Study S000868

Semaglutide for Reducing Cardiovascular Events in Patients Undergoing Transcatether Aortic Valve Replacement

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07090343
Acronym: REVERSE-TAVR
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 826
Start: 2026-04-01
Primary completion: 2030-09-01
Lead sponsor: Leiden University Medical Center
Conditions: Aortic Stenosis; Heart Failure
Interventions: DRUG:Wegovy ®; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

CV death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for HF [From randomization through 12 and 27 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0019192	Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Kosiborod MN, Lancet (London, England)	2024	Randomized trial	PMID 39222642 DOI	registry reference BACKGROUND:39222642
R0022278	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso SP, The New England journal of medicine	2016	Randomized trial	PMID 27633186 DOI	registry reference BACKGROUND:27633186